Ajanta Pharma Ltd. reported outstanding financial results. The company achieved significant growth in the third quarter of fiscal year 2026. This performance highlights its robust business strategy.
Financial Highlights for Q3 FY26
Revenue from operations reached INR 1,375 crore. This marks a strong 20% increase compared to the previous year. For the first nine months of FY26, revenue climbed to INR 4,031 crore. Profit After Tax (PAT) saw an impressive 18% rise. PAT stood at INR 274 crore for the quarter. The company’s EBITDA also grew robustly. It reached INR 382.5 crore, up 19.2% year-on-year. Margins remained healthy and stable. Return on Capital Employed (RoCE) was a strong 34%.
US Generics Drive Significant Growth
The company’s US generics business was a key growth driver. This segment experienced a remarkable 52% surge in Q3 FY26. This expansion was fueled by strategic new product launches. Eight new products contributed to this success. This performance underscores Ajanta Pharma’s expanding global reach.
India Branded Generics Outperform
Domestically, the India branded generics business showed solid gains. Revenue from this segment grew by 19% year-on-year. This performance significantly outpaced the Indian pharmaceutical market. Ajanta Pharma’s growth rate was 11% compared to the market’s 9%. The company continues to launch new products in India. Sixteen new products supported this segment’s growth.
Expanding Global Brand Presence
Ajanta Pharma’s branded generics business across Asia and Africa also contributed positively. Africa’s branded business saw a 33% revenue increase in Q3 FY26. The company strategically focuses on strengthening its brand presence in these regions. This diversification provides resilience and growth opportunities.
Focus on Innovation and New Products
The company maintains a strong commitment to innovation. Research and development spending remains a priority. This focus supports a pipeline of new specialty and complex products. In December 2025, Ajanta Pharma partnered with Biocon. They entered an in-licensing agreement for Semaglutide. This is a key GLP-1 receptor agonist for diabetes. Ajanta Pharma will market this product in 23 countries. It will also have semi-exclusive rights in three more markets across Africa, the Middle East, and Central Asia. This strategic product launch is expected in late 2026 or early 2027. It highlights their strategy to expand their specialty product portfolio. This new product innovation is crucial for emerging markets. It also reinforces their established brand franchise in chronic therapies.
Outlook for Sustained Growth
Ajanta Pharma is strategically positioned for continued success. The company focuses on launching new products. It aims to increase market share. Expansion into new countries and therapies remains a core objective. Management expressed confidence in scaling new products. Their strong on-ground presence supports this. The company is set to leverage its diversified business model. This approach ensures sustained future growth and profitability.
